PPARA and metabolic dysfunction-associated steatohepatitis: An example of such a drug is Lanifibranor, a pan-PPAR (peroxisome proliferator–activated receptor) agonist, which affects crucial metabolic, inflammatory, and fibrogenic processes in NASH development (110).